The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis - PubMed
3 hours ago
- #adolescent health
- #burosumab
- #X-linked hypophosphataemia
- Study focuses on adolescents with X-linked hypophosphataemia (XLH) treated with burosumab at the end of skeletal growth.
- Burosumab is a monoclonal antibody targeting fibroblast growth factor 23, correcting phosphate homeostasis in XLH patients.
- Low symptom severity scores were reported for pain, stiffness, and fatigue, with minimal interference in daily life.
- Some adolescents expressed emotional concerns related to XLH and transitioning to adult care.
- The study utilized patient-reported outcomes, wearable devices, and interviews for a mixed-methods analysis.
- Findings aim to improve patient support during the transition from pediatric to adult healthcare.